Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to
assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA)
phenprocoumon in patients with NVAF and ESKD on hemodialysis. The safety will be assessed by
means of the incidence of major and clinically relevant, non-major bleeding on
anticoagulation.
Phase:
Phase 3
Details
Lead Sponsor:
Atrial Fibrillation Network German Atrial Fibrillation Network